Form Type and Date: This is a Form 8-K current report filed by Abbott Laboratories on August 20, 2026, reporting events as of that same date. Items Reported: The filing indicates it contains disclosures under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). Company Information: Abbott Laboratories is incorporated in Illinois,…

Our analysis rates this filing BEARISH. Abbott faces a HIGH concern level (7.2/10) driven by three material factors: (1) A $670 million realized litigation settlement that converts contingent liability to actual cash obligation, representing meaningful financial impact; (2) An appellate loss that…

Concern level: HIGH (7.2/10). Key factors: Three new high-severity risks identified with average severity 8.0/10, including $670M realized litigation liability; Material $670 million cash settlement commitment represents significant financial impact and converts contingent to realized liability; Appellate loss in Gill case (Missouri Court of Appeals affirmed $495M verdict May 2026) eliminated…

Notable risk changes: Material $670 million cash settlement commitment for NEC litigation - converts contingent liability to realized expense, representing significant financial impact; Remaining 1,700 pending lawsuits (85% of original case volume) indicate settlement may not substantially resolve litigation as company hoped, creating ongoing tail risk; Appellate loss in Gill case (Missouri Court of Appeals affirmed…

The model predicts ABT will outperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.